Breast cancer relapse prediction based on multi-gene RT-PCR algorithm

Medical Science Monitor

Volumn 16, Issue 3, 2010, Pages

  Płuciennik, Elzbieta ^a   Krol, Maciej ^a   Nowakowska, Magdalena ^a   Kusińska, Renata ^a   Potemski, Piotr ^a   Kordek, Radzisław ^a   Bednarek, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Gene expression; Prognostic markers

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ALGORITHM; ARTICLE; BAX GENE; BCL2 GENE; BIRC5 GENE; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CCNE1 GENE; CDH GENE; DISEASE FREE SURVIVAL; DISEASE MARKER; ESR1 GENE; FEMALE; GENE; GENE EXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KRT14 GENE; KRT17 GENE; KRT5 GENE; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WWOX GENE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77649247026     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Saimura M, Fukutomi T, Tsuda H et al: Prognosis of a Series of 763 Consecutive Node-Negative Invasive Breast Cancer Patients Without Adjuvant Therapy: Analysis of Clinicopathological Prognostic Factor. J Surg Oncol, 1999; 71(2): 101-5
2. Teschendorff AE, Miremadi A, Pinder SE et al: An Immune Response Gene Expression Module Identifies a Good Prognosis Subtype in Estrogen Receptor Negative Breast Cancer. Genome Biol, 2007; 8(8): R157
3. 't Veer LJ, Dai H, van de Vijver MJ et al: Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer. Nature, 2002; 415(6871): 530-36
4. Sorlie T, Perou CM, Tibshirani R et al: Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses With Clinical Implications. Proc Natl Acad Sci U.S.A., 2001; 98(19): 10869-74
5. Sotiriou C, Neo SY, McShane LM et al: Breast Cancer Classification and Prognosis Based on Gene Expression Profiles From a Population-Based Study. Proc Natl Acad Sci U.S.A., 2003; 100(18): 10393-98
6. van de Vijver MJ, He YD, van't Veer LJ et al: A Gene-Expression Signature As a Predictor of Survival in Breast Cancer. N Engl J Med, 2002; 347(25): 1999-2009
7. Paik S, Shak S, Tang G et al: A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med, 2004; 351(27): 2817-26
8. Teschendorff AE, Caldas C: A Robust Classifier of High Predictive Value to Identify Good Prognosis Patients in ER-Negative Breast Cancer. Breast Cancer Res, 2008; 10(4): R73
9. Glinsky GV, Higashiyama T, Glinskii AB: Classification of Human Breast Cancer Using Gene Expression Profiling As a Component of the Survival Predictor Algorithm. Clin Cancer Res, 2004; 10(7): 2272-83
10. Pfaffl MW, Horgan GW, Dempfle L: Relative Expression Software Tool (REST) for Group-Wise Comparison and Statistical Analysis of Relative Expression Results in Real-Time PCR. Nucleic Acids Res, 2002; 30(9): e36
11. Camp RL, Dolled-Filhart M, Rimm DL: X-Tile: a New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res, 2004; 10(21): 7252-59
12. Egan WJ, Morgan SL: Outlier Detection in Multivariate Analytical Chemical Data. Analytical chemistry, 2009; 70: 2372-79
13. Aqeilan RI, Croce CM: WWOX in Biological Control and Tumorigenesis. J Cell Physiol, 2007; 212(2): 307-10
14. Hezova R, Ehrmann J, Kolar Z: WWOX, a New Potential Tumor Suppressor Gene. Biomed. Pap. Med. Fac. Univ Palacky. Olomouc Czech Repub, 2007; 151(1): 11-15
15. Iliopoulos D, Guler G, Han SY et al: Roles of FHIT and WWOX Fragile Genes in Cancer. Cancer Lett, 2006; 232(1): 27-36
16. Bednarek AK, Keck-Waggoner CL, Daniel RL et al: WWOX, the FRA16D Gene, Behaves As a Suppressor of Tumor Growth. Cancer Res, 2001; 61(22): 8068-73
17. Guler G, Uner A, Guler N et al: Concordant Loss of Fragile Gene Expression Early in Breast Cancer Development. Pathol Int, 2005; 55(8): 471-78
18. Guler G, Uner A, Guler N et al: The Fragile Genes FHIT and WWOX Are Inactivated Coordinately in Invasive Breast Carcinoma. Cancer, 2004; 100(8): 1605-14
19. Nunez MI, Ludes-Meyers J, Abba MC et al: Frequent Loss of WWOX Expression in Breast Cancer: Correlation With Estrogen Receptor Status. Breast Cancer Res. Treat, 2005; 89(2): 99-105
20. Rakha EA, El Sayed ME, Green AR at al: Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor Positive Phenotype. J Clin Oncol, 2007; 25(30): 4772-78
21. Potemski P, Pluciennik E, Bednarek AK et al: Evaluation of Oestrogen Receptor Expression in Breast Cancer by Quantification of MRNA. Histopathology, 2007; 51(6): 829-36
22. Lei H, Sjoberg-Margolin S, Salahshor S et al: CDH1 Mutations Are Present in Both Ductal and Lobular Breast Cancer, but Promoter Allelic Variants Show No Detectable Breast Cancer Risk. Int J Cancer, 2002; 98(2): 199-204
23. Droufakou S, Deshmane V, Roylance R et al: Multiple Ways of Silencing E-Cadherin Gene Expression in Lobular Carcinoma of the Breast. Int J Cancer, 2001; 92(3): 404-8
24. Nass SJ, Herman JG, Gabrielson E et al: Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5' CpG Islands Increases With Malignant Progression in Human Breast Cancer. Cancer Res, 2000; 60(16): 4346-48
25. Heimann R, Lan F, McBride R, Hellman S: Separating Favorable From Unfavorable Prognostic Markers in Breast Cancer: the Role of E-Cadherin. Cancer Res, 2000; 60(2): 298-304
26. Perou CM, Sorlie T, Eisen MB et al: Molecular Portraits of Human Breast Tumors. Nature, 2000; 406(6797): 747-52
27. van de Rijn M, Perou CM, Tibshirani R et al: Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas With Poor Clinical Outcome. Am J Pathol, 2002; 161(6): 1991-96
28. Foulkes WD, Brunet JS, Stefansson IM et al: The Prognostic Implication of the Basal-Like (Cyclin E High/P27 Low/P53+/Glomeruloid-Microvascular- Proliferation+) Phenotype of BRCA1-Related Breast Cancer. Cancer Res, 2004; 64(3): 830-35
29. Lindahl T, Landberg G, Ahlgren J et al: Overexpression of Cyclin E Protein Is Associated With Specific Mutation Types in the P53 Gene and Poor Survival in Human Breast Cancer. Carcinogenesis, 2004; 25(3): 375-80
30. Berardo MD, Elledge RM, de Moor C et al: Bcl-2 and Apoptosis in Lymph Node Positive Breast Carcinoma. Cancer, 1998; 82(7): 1296-302
31. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in Breast Cancer As Related to Histopathological Characteristics and Prognosis. Eur J Cancer, 1994; 30A(14): 2068-73
32. Yang Q, Sakurai T, Jing X et al: Expression of Bcl-2, but Not Bax, Correlates With Estrogen Receptor Status and Tumor Proliferation in Invasive Breast Carcinoma. Pathol Int, 1999; 49(9): 775-80
33. Adida C, Crotty PL, McGrath J et al: Developmentally Regulated Expression of the Novel Cancer Anti-Apoptosis Gene Survivin in Human and Mouse Differentiation. Am J Pathol, 1998; 152(1): 43-49
34. Ryan BM, Konecny GE, Kahlert S et al: Survivin Expression in Breast Cancer Predicts Clinical Outcome and Is Associated With HER2, VEGF, Urokinase Plasminogen Activator and PAI-1. Ann Oncol, 2006; 17(4): 597-604